Oral and inhaled p38 MAPK inhibitors: Effects on inhaled LPS challenge in healthy subjects

European Journal of Clinical Pharmacology

Volumn 71, Issue 10, 2015, Pages 1175-1184

  Singh, Dave ^a   Siew, Leonard ^b   Christensen, Jared ^c   Plumb, Jonathan ^a   Clarke, Graham W ^b,d   Greenaway, Steve ^b   Perros Huguet, Christelle ^c   Clarke, Nick ^c   Kilty, Iain ^c   Tan, Lisa ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b IQVIA   (United States)

^c PFIZER INC   (United States)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Induced sputum; LPS challenge; p38 MAPK inhibitors

Indexed keywords

3 [3 BROMO 4 (2,4 DIFLUOROBENZYLOXY) 6 METHYL 2 OXO 1(2H) PYRIDINYL] N,4 DIMETHYLBENZAMIDE; C REACTIVE PROTEIN; CYTOKINE; FLUTICASONE PROPIONATE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PF 03715455; PROTEIN CC16; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; AUTACOID; AZABICYCLO DERIVATIVE; BENZAMIDE DERIVATIVE; FLUTICASONE; METHYLUREA; MITOGEN ACTIVATED PROTEIN KINASE P38; PYRIDONE DERIVATIVE;

ADULT; ARTICLE; BLOOD SAMPLING; CELLULITIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRY POWDER INHALER; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; INHALER; MALE; NEUTROPHIL; NEUTROPHIL COUNT; NEUTROPHILIC AIRWAY INFLAMMATION; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; SINGLE DRUG DOSE; SINGLE PIN MONODOSE INHALER; SPUTUM; SPUTUM ANALYSIS; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CYTOLOGY; DOUBLE BLIND PROCEDURE; INFLAMMATION; INHALATION TEST; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; AZABICYCLO COMPOUNDS; BENZAMIDES; BRONCHIAL PROVOCATION TESTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FLUTICASONE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MALE; METHYLUREA COMPOUNDS; MIDDLE AGED; NEUTROPHILS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDONES; SPUTUM; YOUNG ADULT;

EID: 84941315721     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-015-1920-1     Document Type: Article

References (24)

1. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350(26):2645-53
2. Cazzola M, Page CP, Calzetta L, Matera MG (2012) Emerging anti-inflammatorystrategies for COPD. Eur Respir J 40:724-41
3. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, TORCH Investigators (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356:775-89
4. Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, Pavord ID (2000) Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 356:1480-5
5. Saklatvala J (2004) The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol 4:372-377
6. Gaffey K, Reynolds S, Plumb J, Kaur M, Singh D (2013) Increased phosphorylated p38 mitogen activated protein kinase in COPD lungs. Eur Respir J 42:28-41
7. Renda T, Baraldo S, Pelaia G, Bazzan E, Turato G, Papi A, Maestrelli P, Maselli R, Vatrella A, Fabbri LM, Zuin R, Marsico SA, Saetta M (2008) Increased activation of p38 MAPK in COPD. Eur Respir J 31:62-69
8. Chung KF (2011) P38 mitogen-activated protein kinase pathways in asthma and COPD. Chest 139:1470-9
9. Armstrong J, Harbron C, Lea S, Booth G, Cadden P, Wreggett KA, Singh D (2011) Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease. J Pharmacol Exp Ther 338:732-740
10. Singh D, Smyth L, Borrill Z, Sweeney L, Tal-Singer R (2010) A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. J Clin Pharmacol 50:94-100
11. Lomas DA, Lipson DA, Miller BE, Willits L, Keene O, Barnacle H, Barnes NC, Tal-Singer R, Losmapimod Study Investigators (2012) An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol 52:416-424
12. Macnee W, Allan RJ, Jones I, De Salvo MC, Tan LF (2013) Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial. Thorax 68:738-745
13. Watz H, Barnacle H, Hartley B, Chan R (2014) Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2:63-71
14. Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, Strand V, Baker DG, Tong SE (2011) A 24 weeks, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol 38:846-54
15. Nightingale JA, Rogers DF, Hart LA, Kharitonov SA, Chung KF, Barnes PJ (1998) Effect of inhaled endotoxin on induced sputum in normal, atopic, and atopic asthmatic subjects. Thorax 53:563-71
16. Michel O, Dentener M, Cataldo D, Cantinieaux B, Vertongen F, Delvaux C, Murdoch RD (2007) Evaluation of oral corticosteroids and phosphodiesterase-4 inhibitor on the acute inflammation induced by inhaled lipopolysaccharide in human. Pulm Pharmacol Ther 20:676-83
17. Leaker BR, Barnes PJ, O'Connor B (2013) Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist. Respir Res 14:137
18. Roos-Engstrand E, Wallin A, Bucht A, Pourazar J, Sandström T, Blomberg A (2005) Increased expression of p38 MAPK in human bronchial epithelium after lipopolysaccharide exposure. Eur Respir J 25:797-803
19. Ovrevik J, Låg M, Holme JA, Schwarze PE, Refsnes M (2009) Cytokine and chemokine expression patterns in lung epithelial cells exposed to components characteristic of particulate air pollution. Toxicology 259:46-53
20. Pizzichini E, Pizzichini MM, Efthimiadis A, Evans S, Morris MM, Squillace D, Gleich GJ, Dolovich J, Hargreave FE (1996) Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 154:308-17
21. Moretto N, Bertolini S, Iadicicco C, Marchini G, Kaur M, Volpi G, Patacchini R, Singh D, Facchinetti F (2012) Cigarette smoke and its component acrolein augment IL-8/CXCL8 mRNA stability via p38 MAPK/MK2 signaling in human pulmonary cells. Am J Physiol Lung Cell Mol Physiol 303:L929-38
22. Gupta V, Banyard A, Mullan A, Sriskantharajah S, Southworth T, Singh D (2015) Characterization of the inflammatory response to inhaled lipopolysaccharide in mild to moderate chronic obstructive pulmonary disease. Br J Clin Pharmacol 79:767-76
23. Ketchell RI, Jensen MW, Lumley P, Wright AM, Allenby MI, O'Connor BJ (2002) Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5′-monophosphate in mild asthma. J Allergy Clin Immunol 110:603-6
24. Parameswaran K, Inman MD, Watson RM, Morris MM, Efthimiadis A, Ventresca PG, Lam R, O'Byrne PM, Hargreave FE (2000) Protective effects of fluticasone on allergen-induced airway responses and sputum inflammatory markers. Can Respir J 7:313-9